MétaCan
Menu
Back to cohort
Record W6889801701 · doi:10.26190/81wp-fr56

Monitoring hepatitis C treatment uptake in Australia: Issue #13, July 2023

2023· report· en· W6889801701 on OpenAlexaboutno aff

Bibliographic record

VenueUNSWorks (University of New South Wales, Sydney, Australia) · 2023
Typereport
Languageen
Field
Topic
Canadian institutionsnot available
Fundersnot available
KeywordsDiscontinuationMedical prescriptionAntiviral treatmentHepatitis C virusHepatitis CQuarter (Canadian coin)

Abstract

fetched live from OpenAlex

A total of 105,024 individuals have initiated direct acting antiviral (DAA) treatment for chronic hepatitis C virus (HCV) infection in Australia, including 100,684 individuals through Pharmaceutical Benefits Scheme (PBS) during 2016 to 2022, and an estimated 4,340 individuals through early DAA access avenues in 2014-15. In 2022, 5,205 individuals initiated treatment (first course), increasing from 1,141 in the first quarter to 1,432 in the last quarter of 2022. The recent increase in treatment uptake could be explained by enhanced HCV testing programs implemented in the community and prisons in several jurisdictions. Among individuals initiating DAA treatment during 2016 to 2022 (n=100,684), 68% were men, and median age was 47 years (quartiles 1-3: 38-57). Since August 2018 when both pan-genotypic regimens were available (i.e., sofosbuvir/velpatasvir and glecaprevir/pibrentasvir), 53% of individuals have been initiated on sofosbuvir/velpatasvir, 41% on glecaprevir/pibrentasvir, and 6% on other regimens. Most individuals initiating DAA treatment received their prescriptions from general practitioners (GPs; 46%), followed by gastroenterologists (35%). Overall, 52% of individuals were initiated on treatment by specialists, and 48% by non-specialists (i.e., GPs and nurse practitioners). A total of 2,048 individuals were initiated on treatment by nurse practitioners, increasing from 92 in 2017 to 535 in 2022. Among individuals initiating DAA treatment during 2016 to 2022, 8.6% discontinued treatment, including 4.0% early discontinuation (i.e., dispensed 28 days of treatment) and 4.6% late discontinuation (i.e., dispensed at least 56 days of treatment, but not all recommended duration). The proportion of early discontinuation increased from >3% in 2016 to 8.5% in mid-2021 followed by a plateau phase and then slight decrease in 2022. Among individuals who discontinued treatment, 26% received re-treatment. Among individuals initiating DAA treatment during 2016 to 2022, 8.5% received at least one course of re-treatment. Among re-treatment initiations, an estimated 57% were for HCV re-infection and 43% for treatment failure. The number of re-treatment initiations for treatment failure increased during the second quarter of 2019, corresponding to sofosbuvir/velpatasvir/voxilaprevir availability through PBS (April 2019), and has decreased since. The number of re-treatment initiations for HCV re-infection increased until mid-2020, stabilised during 2020-21, and increased again in 2022. This latest increase could be the result of enhanced HCV testing programs implemented in several jurisdictions through which many individuals with HCV re-infection were diagnosed and linked to clinical care.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Research integrity, Insufficient payload (model declined to judge)
Consensus categoriesMeta-epidemiology (narrow), Research integrity, Insufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.743
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0020.003
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0030.004
Science and technology studies0.0000.001
Scholarly communication0.0000.001
Open science0.0020.001
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.0030.021

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.224
GPT teacher head0.348
Teacher spread0.124 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueUNSWorks (University of New South Wales, Sydney, Australia)French-language works237,207